GHRP-6
Also known as: Growth Hormone Releasing Peptide 6
limited human dataWADA bannedNot FDA approvedResearch only
Published Dose Range
Low100 mcg/dose
Typical100-200 mcg 2-3x/day
High300 mcg/dose
Potent ghrelin mimetic with strong appetite stimulation. Pulses better than higher single doses.
Published Cycle Range
Short4 wks
Typical8 wks
Long12 wks
Receptor desensitization possible with chronic dosing — cycle off periodically.
Off-cycle: 4 weeks
Administration
Routessubcutaneous
Frequency2-3x daily
Preferred timingPre-bed, post-workout, fasted
AvoidAvoid carbs/fats within 1 hour (blunts GH pulse)
Typical: morning, post-workout, pre-bed stack with GHRH.
Safety Profile
Contraindications
- • Cancer history
- • Uncontrolled diabetes
Common side effects
- • Marked appetite increase (ghrelin receptor agonist)
- • Water retention
- • Injection site reactions
- • Mild cortisol/prolactin elevation
Serious risks
- • Prolonged use may promote insulin resistance
- • Cortisol/prolactin elevation higher than Ipamorelin
Requires monitoring
- • IGF-1 levels
- • Blood glucose if chronic use
Pregnancy / breastfeeding
No data — consult clinician
Common Misconceptions
- Not interchangeable with Ipamorelin — elevates cortisol and prolactin
- Appetite effect is much stronger than GHRP-2
Commonly Stacked With
CJC-1295Sermorelin
- Avoid stacking with other GHRPs — receptor competition with no additive benefit
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.